Elsevier

Journal of Autoimmunity

Volume 31, Issue 2, September 2008, Pages 166-174
Journal of Autoimmunity

Comparative qualitative and quantitative analysis of scleroderma (systemic sclerosis) serologic immunoassays

https://doi.org/10.1016/j.jaut.2008.07.001Get rights and content

Abstract

The heterogeneity of autoantibody specificities occurring in sera from patients with systemic sclerosis (SSc) raised the necessity of developing various methodologies for their detection. A cohort of 150 SSc patients were selected and tested by Indirect Immunofluorescence (IIF), Counterimmunoelectrophoresis (CIE), Immunoblot (IB) using various extracts as antigenic source and RNA precipitation. By preparing a nuclear (IB-nuclear) and a metaphase chromosomal-enriched extract (IB-MC-pellet) from HeLa cells as well as a nucleolar (IB-nucleolar) and a histone (IB-histone) extract from rat liver nuclei, we assessed their sensitivity and specificity for anti-Topo I, anti-U3RNP, anti-H1, anti-snRNPs antibodies and ACA. IB-nuclear revealed the highest frequency of anti-Topo I antibodies, while CIE, IB-nucleolar and IB-MC-pellet, when compared to IB-nuclear showed a sensitivity of 89%, 87% and 95%, respectively. IB-MC-pellet was unique for ACA recognition, while IB-nucleolar and IB-MC-pellet showed excellent sensitivity for anti-U3RNP and anti-H1 antibody detection. We conclude that IB-nuclear is a highly sensitive system for anti-Topo I antibodies determination, but CIE reveals a good sensitivity to be used as a first screening test. IB-nucleolar or IB-MC-pellet are important techniques to detect the variety of antibodies to nucleolus and chromatin-related constituents. A novel specificity against a 28 kD nucleolar protein, non-associated with RNAs is also presented.

Introduction

Systemic sclerosis (SSc) is a chronic multisystemic disorder of unknown etiology characterized by vascular damage and by deposition of collagen in various tissues [1]. SSc-specific autoantibody profiles to a variety of cellular components [2], [3] are strongly associated with distinct clinical phenotypes making serologic testing of great diagnostic aid [4]. The most prominent ones are anti-topoisomerase I (Topo I), anti-centromere (ACA) and anti-nucleolar antibodies [5]. Anti-Topo I antibodies occur in patients with diffuse systemic sclerosis (dSSc) and have been associated with pulmonary involvement and digital ulcers [6] whereas anticentromere antibodies are mainly detected in patients with limited systemic sclerosis (lSSc) [2], [7], [8].

ACA recognize the centromere proteins A, B, and C (CENP-A, 17 kD; CENP-B, 80 kD; CENP-C, 140 kD) as shown by Immunoblots using nuclear constituents as antigen source [9], [10]. Topo I is a nuclear enzyme responsible for interconverting different topological forms of DNA [11]. Anti-Topo I antibodies can be detected either by Immunoblots of purified HeLa cell chromosome or nuclei and/or by Immunoblots on fragments of recombinant topoisomerase I [12], [13]. It has also been proved that ELISA with purified topoisomerase I as antigen source can provide a useful diagnostic and prognostic tool [14] and it is more sensitive than gel diffusion and more specific than Immunoblot but anti-Topo I detection improvement is still investigated [13], [15].

Several antibodies targeting nucleolar antigens are found most frequently in patients suffering from SSc and overlap syndromes [16], [17], [18]. Antinucleolar antibodies (ANoA) are almost exclusively detected in SSc patients' sera by immunoprecipitation assays including antibodies against the U3 small nucleolar RNP (U3snoRNP) complex or fibrillarin [19], [20], [21], [22], [23], the PM–Scl complex [24], [25], the nucleolar 7–2 RNA (Th/To ribonucleoprotein) [23], [26], [27], the upstream binding factor NOR-90 [28] and the nucleolar phosphoprotein B23 [29].

A number of studies have demonstrated the presence of autoantibodies against the three classes of RNA polymerases detected by immunoprecipitation assays using 35S-methionine radiolabelled extracts and ELISA testing [30], [31], [32], [33], [34].

Furthermore, additional autoantibody specificities such as anti-histone antibodies (AHA) detected by ELISA and Immunoblot [35] in SSc patients' sera, autoantibodies to pyruvate dehydrogenase complex also detected by ELISA and Immunoblot [36] and antiubiquitin antibodies detected by ELISA [37] have been described. The prevalence of anti-U1RNA antibodies [38] and the presence of anti-U5 snRNPs as possible scleroderma-associated serologic marker [39] have been recently reported.

The heterogeneity of autoantibody populations appearing in SSc, and the difficulty of their detection by routine assays such as Indirect Immunofluorescence (IIF) or Counterimmunoelectrophoresis (CIE), raise the necessity of developing sensitive and specific techniques for their identification. To study the variety of autoantibody specificities appearing in SSc patients' sera, four methods have been applied including IIF, CIE, Immunoblot on nuclear extract and different subfractions of nuclei as well as RNA precipitation; the sensitivity and specificity of these assays were assessed. Selected sera from well characterized patients covering all the disease variants (dSSc, lSSc, overlap syndrome) and their related clinical characteristics were used in the present study.

Section snippets

Sera

Serum samples from 150 patients with SSc were selected for this study. Patients were outpatients from the rheumatology clinic of Ioannina University Hospital and the rheumatology clinic of Laikon University Hospital of Athens and included 84 patients with lSSc, 54 with dSSc and 12 with overlap syndrome. The diagnoses were based on the Le Roy criteria [40]. Serum samples from 20 blood donors were included in the study. Reference sera for anti-U3RNP and anti-Th/To antibodies were kindly provided

Immunoblot with nuclear HeLa cell extract (IB-nuclear)

Nuclear HeLa cell extract was prepared as previously described [42]. Briefly 2.5 × 107 cells/ml were suspended in buffer A containing 10 mM Tris–HCl, 100 mM NaCl, 2.5 mM MgCl2, 0.5% v/v Triton X-100 and 2 μg/ml pepstatin, leupeptin, aprotinin. After homogenization with a type-S pestle and centrifugation at 4000 rpm for 10 min at 4 °C, the nuclei were separated, resuspended in buffer A and then sonicated on ice twice for 5 s while the temperature was maintained below 4 °C. The sonicate was then layered on a

Definition of sensitivity and specificity/statistical analysis

Sensitivity of a method is defined as the percentage (%) of the number of positive results found by this method towards the real positive results obtained by the reference method.

Specificity of a method is defined as the percentage (%) of the number of negative results found by this method towards the real negative results obtained by the reference method.

Clinical characteristics of the selective SSc patient population studied

One hundred fifty patients with SSc variants, either lSSc (n = 84), dSSc (n = 54) or overlap syndrome (n = 12) were evaluated for their autoantidody profile. As shown in Table 1, the above patients were completely representative of a severe Scleroderma patients' cohort. A large proportion of these patients have noticed digital ulcers, telangiectasias and esophageal dysmotility associated symptoms such as dysphagia or retrosternal burning sensation. A small proportion of lSSc patients gradually

Discussion

Immunoblot techniques have been extensively used to detect autoantibodies to nuclear and cytoplasmic antigens associated with rheumatic diseases, and serologic as well as clinical correlations have been described [55]. In the present study we were able to identify various autoantibody specificities relatively specific for SSc, such as anti-Topo I, ACA, anti-fibrillarin/U3RNP, and other specificities not directly correlated with the disease, by means of Immunoblot using different crude extracts

References (79)

  • B.C. Gilliland

    Systemic sclerosis (scleroderma)

  • T.A. Medsger

    Systemic sclerosis (scleroderma), eosinophilic fasciitis, and calcinosis

  • V.D. Steen et al.

    Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis

    Arthritis Rheum

    (1988)
  • M.L. Harris et al.

    Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies

    Curr Opin Rheumatol

    (2003)
  • J.G. Walker et al.

    Update on autoantibodies in systemic sclerosis

    Curr Opin Rheumatol

    (2007)
  • E.S. Weiner et al.

    Clinical associations of anti-centromere antibodies and antibodies to topoisomerase I: a study of 355 patients

    Arthritis Rheum

    (1988)
  • W.C. Ernshaw et al.

    Three human chromosomal autoantigens are recognized by sera from patients with anticentromere antibodies

    J Clin Invest

    (1986)
  • J.C. Wang

    DNA topoisomerases

    Annu Rev Biochem

    (1985)
  • P. D'Arpa et al.

    Use of molecular cloning methods to map the distribution of epitopes on topoisomerase I (Scl-70) recognized by sera of scleroderma patients

    Arthritis Rheum

    (1990)
  • N. Bizzaro et al.

    Sensitivity and specificity of immunological methods for the detection of anti-topoisomerase I (Scl70) autoantibodies: results of a multicenter study

    Clin Chem

    (2000)
  • J. Whyte et al.

    Detection of anti-topoisomerase antibodies using a full length human topoisomerase I recombinant protein purified from a bacullovirus expression system

    Clin Exp Immunol

    (1995)
  • M. Reichlin et al.

    Antibodies to nuclear/nucleolar antigen in patients with polymyocitis overlap syndrome

    J Clin Immunol

    (1984)
  • H. Van Eenennaam et al.

    Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations

    Clin Exp Immunol

    (2002)
  • G. Reimer et al.

    Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma)

    Arthritis Rheum

    (1988)
  • Y. Okano et al.

    Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis

    Arthritis Rheum

    (1992)
  • J.M. Yang et al.

    Human scleroderma sera contain autoantibodies to protein components specific to the U3 small nucleolar rnp complex

    Arthritis Rheum

    (2003)
  • R.J. Kipnis et al.

    The autoantibodies of antinuclear and antinucleolar autoantibodies of scleroderma by radioimmunoprecipitation assay

    Arthritis Rheum

    (1990)
  • K.N. Kasturi et al.

    Anti-fibrillarin autoantibodies present in systemic sclerosis and other connective tissue diseases interact with similar epitopes

    J Exp Med

    (1995)
  • C.V. Oddis et al.

    Serum autoantibody to the nucleolar antigen PM-Scl

    Arthritis Rheum

    (1992)
  • M. Malher et al.

    Novel aspects of autoantibodies to the PM/Scl complex. Clinical, genetic and diagnostic insights

    Autoimmun Rev

    (2007)
  • Y. Okano et al.

    Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis

    Arthritis Rheum

    (1990)
  • K. Yamane et al.

    Antibodies to Th/To ribonucleoporotein in patients with localized scleroderma

    Rheumatology

    (2001)
  • H. Imai et al.

    Immunocytochemical characterization of human NOR-90 (upstream binding factor) and associated antigens reactive with autoimmune sera

    Mol Biol Rep

    (1994)
  • D. Ulanet et al.

    Autoantibodies against B23, a nucleolar phosphoprotein, occur in scleroderma and are associated with pulmonary hypertension

    Arthritis Rheum

    (2003)
  • G. Reimer et al.

    Autoantibody to RNA polymerase I in scleroderma sera

    J Clin Invest

    (1987)
  • M. Kuwana et al.

    Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis

    J Clin Invest

    (1993)
  • Y. Yamasaki et al.

    Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies

    Arthritis Rheum

    (2006)
  • A. Bardoni et al.

    Autoantibodies to RNA-polymerases in Italian patients with systemic sclerosis

    Clin Exp Rheumatol

    (2003)
  • M. Kuwana et al.

    Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody

    Arthritis Rheum

    (2005)
  • View full text